<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740363</url>
  </required_header>
  <id_info>
    <org_study_id>JANUVIA-08</org_study_id>
    <nct_id>NCT00740363</nct_id>
  </id_info>
  <brief_title>Sitagliptin in Renal Transplant Recipients</brief_title>
  <official_title>The Effect of Sitagliptin Treatment on Glucose Metabolism and Endothelial Function in Renal Transplant Recipients - JANUVIA-08</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo School of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo School of Pharmacy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major cause of premature death in renal transplant recipients is cardiovascular disease.
      Sitagliptin stimulates insulin secretion and inhibits glucagon release, two central
      mechanisms in PTDM by interaction with a hormone system (incretins) that just recently it has
      become possible to modulate by drugs. Sitagliptin therefore is an interesting additional drug
      for the treatment of posttransplant diabetes mellitus in transplanted patients.

      The primary objective of the present study is to investigate the effect of sitagliptin on
      insulin secretion in renal transplant recipients.

      Secondary objectives are to study the effect on insulin sensitivity, fasting blood glucose,
      endothelial function, CsA/Tac blood concentrations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclosporine/tacrolimus blood concentrations</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Glucose Intolerance</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 weeks of treatment with sitagliptin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No treatment for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>Once daily sitagliptin. If GFR&gt;50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>No active sitagliptin treatment for 4 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant recipient more than 1 year posttransplant with stable renal function
             (less than 20% deviation in serum creatinine the last 2 months) and stable
             prednisolone dose for the last 3 months before inclusion.

          -  Patients in need of (additional) oral anti-diabetic treatment:

               -  New onset diabetes patients with fasting plasma glucose 7-8 mmol/ l, and/or 2-hr
                  plasma glucose 12-18 mmol/l after an oral glucose tolerance test (OGTT)

               -  Patients already on oral hypoglycemic therapy, but with HbA1c 8-11%

          -  18 years of age.

          -  Male patient, or female patient without childbearing potential (surgically sterilized
             or postmenopausal) or, if female of childbearing potential, is not lactating, has a
             negative pregnancy test at screening and is willing to utilize an effective method of
             contraception throughout the study period and for 90 Days following discontinuation of
             the Study Drugs.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Treatment with insulin

          -  Severe liver disease.

          -  Estimated GFR &lt; 25 ml/min/1.73 m2.

          -  Skin disorders that may influence laser Doppler flowmetry investigations.

          -  Pregnant or nursing mothers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trond Jenssen, MD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rikshospitalet Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rikshospitalet Medical Center</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal transplantation</keyword>
  <keyword>diabetes</keyword>
  <keyword>glucose intolerance</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

